AC Immune Says Active-Immunotherapy Candidate, ACI-35.030 (Now Called JNJ-2056), Targeting Pathologic Form Of Tau Protein Has Received Fast Track Designation From FDA
Portfolio Pulse from Benzinga Newsdesk
AC Immune's active-immunotherapy candidate, ACI-35.030 (now called JNJ-2056), targeting the pathologic form of tau protein, has received Fast Track designation from the FDA.
July 25, 2024 | 11:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AC Immune's active-immunotherapy candidate, ACI-35.030 (JNJ-2056), has received Fast Track designation from the FDA, which could expedite its development and review process.
The Fast Track designation by the FDA is a significant milestone for AC Immune as it can expedite the development and review process of ACI-35.030 (JNJ-2056). This increases the likelihood of the drug reaching the market sooner, which is positive news for investors.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100